Catalysts / ERAS
Upcoming FDA decisions and readouts we track for Erasca, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Erasca (ERAS, listed on Nasdaq). They cover 3 programmes: ERAS-4001 (KRAS-mutant solid tumours (pan-KRAS inhibitor)), ERAS-0015 (RAS-mutant solid tumours (pan-RAS inhibitor)) and ERAS-0015 + panitumumab (RAS-mutant colorectal cancer).
First on the list: the Phase 1 readout for ERAS-4001 (KRAS-mutant solid tumours (pan-KRAS inhibitor)), guided by the company to H2 2026. The furthest-out event tracked is H1 2027. By stage, the upcoming rows are 3 Phase 1 readouts.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Erasca ERAS · Nasdaq | ERAS-4001 | KRAS-mutant solid tumours (pan-KRAS inhibitor) | H2 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Erasca ERAS · Nasdaq | ERAS-0015 | RAS-mutant solid tumours (pan-RAS inhibitor) | H1 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Erasca ERAS · Nasdaq | ERAS-0015 + panitumumab | RAS-mutant colorectal cancer | H1 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList